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Rationale: Adipose tissue produces adiponectin, an anti-inflammatory protein. Adiponectin deficiency in mice is
associated with abnormal post-natal alveolar development.
Objective: We hypothesized that lower serum adiponectin concentrations are associated with lower lung function
in humans, independent of obesity. We explored mediation of this association by insulin resistance and systemic
inflammation.
Methods and Measurements: Spirometry testing was conducted at years 10 and 20 follow-up evaluation visits in
2,056 eligible young adult participants in the Coronary Artery Risk Development in Young Adults (CARDIA) study.
Body mass index, serum adiponectin, serum C-reactive protein (a marker of systemic inflammation), and insulin
resistance were assessed at year 15.
Main Results: After controlling for body mass index, years 10 and 20 forced vital capacity (FVC) were 81 ml and
82 ml lower respectively (p = 0.004 and 0.01 respectively) in the lowest vs. highest adiponectin quartiles. Similarly,
years 10 and 20 forced expiratory volume in one second (FEV1) were 50 ml and 38 ml lower (p = 0.01 and 0.09,
respectively) in the lowest vs. highest adiponectin quartiles. These associations were no longer significant after
adjustment for insulin resistance and C-reactive protein. Serum adiponectin was not associated with FEV1/FVC or
peak FEV1.
Conclusions: Independent of obesity, lower serum adiponectin concentrations are associated with lower lung
function. The attenuation of this association after adjustment for insulin resistance and systemic inflammation
suggests that these covariates are on a causal pathway linking adiponectin and lung function.
Introduction
Adipose tissue produces adipokines, proteins that regu-
late inflammation and metabolism in an autocrine, para-
crine, and systemic manner [1]. Adiponectin is an
adipokine associated with systemic anti-inflammatory
effects and insulin sensitization effects [1]. Serum adipo-
nectin concentrations are reduced in obesity [2,3]. Adi-
ponectin and all of the known receptors for adiponectin
(AdipoR1, AdipoR2, T-cadherin and calreticulin) are
expressed on multiple cell types in the lung [4-7].
Adiponectin is also transported from blood into the
alveolar lining fluid via the T-cadherin molecule on the
endothelium [5].
Various disease states associated with lower serum
adiponectin concentrations (such as obesity, asthma, sys-
temic inflammation, and diabetes mellitus [2,3,8,9]) are
associated with reduced lung function [10-14]. It is
therefore possible that lower serum concentrations of
adiponectin may be associated with decreased lung func-
tion in humans. This hypothesis is supported by a
recent study in normal-weight mice with genetic defi-
ciency of systemic adiponectin. These mice demon-
strated local (lung) adiponectin deficiency, increased
systemic and local inflammation, and “alveolar simplifi-
cation and/or enlargement due to abnormal post-natal
alveolar development” [15].
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serum concentration of adiponectin and lung function
in the prospective Coronary Artery Risk Development in
Young Adults (CARDIA) study. We hypothesized that
lower serum concentrations of adiponectin measured at
year 15 after enrollment in the CARDIA study are asso-
ciated with lower lung function at years 10 and 20 and
ten year decline in lung function. We also hypothesized
that this effect of serum adiponectin concentrations on
lung function is independent of obesity and might be
mediated by its systemic anti-inflammatory and insulin
sensitization effects.
Methods
In the CARDIA study, 5,115 participants aged 18-30
years were recruited for the baseline (year 0) examina-
tion in 1985-86, including approximately equal numbers
who were black and white, men and women, and
≤ twelve-years of education and > twelve-years of educa-
tion. Subsequently, 3,950 participants (77%) were fol-
lowed up in 1995-96 (year 10); 3,672 (72%) in 2000-
2001 (year 15); and 3,549 (69%) in 2005-2006 (year 20)
examinations. The detailed methods, instruments and
quality control procedures for the CARDIA study have
been previously described [10,16]. The CARDIA study is
reviewed annually by the internal review boards at each
participating institution, and participants sign a new
informed consent form at every examination. Demo-
graphic characteristics, lifestyle habits (e.g. cigarette
smoking), physical activity, and medical history were
collected by self-report. The diagnosis of asthma was
made if the subject at any of the study visits self-
reported a doctor or nurse diagnosis of asthma and/or
reported taking asthma medications (usually based on
examination of medicine containers). Spirometry was
performed using a Collins Survey 8-liter water sealed
spirometer and an Eagle II Microprocessor (Warren
E. Collins, Inc., Braintree, MA) at year 10 examination
and a dry rolling-seal OMI spirometer (Viasys Corp,
L o m aL i n d a ,C A )a ty e a r2 0e xamination, adhering to
the American Thoracic Society guidelines. A compar-
ability study performed on 25 volunteers at the LDS
Hospital (Salt Lake City, UT) demonstrated excellent
consistency between the old and new machines; the
average difference between the Collins Survey and OMI
spirometer was 6 ml for FVC and 21 ml for FEV1.T h e
homoeostasis model assessment (HOMA) for estimating
insulin resistance was calculated as serum glucose
(mmol/L)×serum insulin (mU/L)/22·5 [17]. Serum C
reactive protein (CRP) was measured using a high sensi-
tivity new enzyme-linked immunosorbent assay method
at the Department of Pathology, University of Vermont,
Burlington, VT, USA [18].
After excluding participants who were pregnant dur-
ing years 10, 15 or year 20 examination (n = 16), asthma
diagnosis during the 20 years of CARDIA follow-up (n =
408), and those with missing values for either serum
adiponectin (n = 423), year 20 lung function (n = 119),
year 10 lung function (n = 447) or covariates (n = 80),
2,056 participants were included in this study.
Overnight fasting blood samples were collected, pro-
cessed within 90 minutes of blood collection and stored
at -70°C. Total adiponectin was measured in serum by
radioimmunoassay at Linco Research, Inc. (St. Louis,
MO) using a polyclonal antibody raised in a rabbit with
an effective range of 0.2 to 40 mg/L [8]. The correlation
between adiponectin concentrations measured in 407
blinded duplicate samples was 0.91 and the coefficient
of variation (CV) for the adiponectin assay was 17%
(including laboratory measurement error, variation in
specimen handling and freezing and labeling errors).
A previous study demonstrated that serum adiponectin
showed little circadian variability and limited within-per-
son variation over time [19].
Statistical Analysis
We used linear regression (PROC GLM) in SAS, version
9.1 (Cary, NC) to evaluate the associations of year 15
adiponectin concentrations with lung function at years
10 and 20. Quartiles of year 15 adiponectin concentra-
tions (independent variable) were used to predict forced
vital capacity (FVC), forced expiratory volume in one-
second (FEV1)a n dF E V 1/FVC ratio at years 10 and 20
(dependent variables). In addition, the ten-year change
(year 20 - year 10) in FVC, FEV1 and FEV1/FVC was
predicted, using year 15 adiponectin quartiles. Of note,
serum adiponectin measurements at years 10 and 20 or
conversely, spirometric measurement at year 15 were
not available in the CARDIA study. These associations
were adjusted for race, sex, study center, height, height
2,
age, age
2, amount of self-reported physical activity, body
mass index (BMI) and smoking status (never, former,
current), all at year 15 (model 1). These covariates were
selected because of their association with lung function
or adiponectin. Since age and height were not linearly
associated with lung function, age
2 and height
2 were
included in the model to more completely adjust the
effect of age and height on lung function. In addition,
all analyses were performed with adjustment for mea-
sures of insulin resistance (as estimated by HOMA and
systemic inflammation (CRP) (model 2). All these ana-
lyses (models 1 and 2) were also performed with adipo-
nectin as a continuous variable. Adiponectin, HOMA
and CRP were (natural) logarithmically transformed (ln)
due to their skewed distribution. There was no evidence
for collinearity among the covariates (except age-age
2
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2) used in the model. We also analyzed
the association between year 15 serum adiponectin con-
centrations (independent variable) and peak lung func-
tion (FVC, FEV1 and FEV1/FVC) in early adulthood
(dependent variable) using models similar to those
described above in which all the covariates were mea-
sured at year 5. Peak lung function was defined as the
maximum lung function measurement at any of the
three initial CARDIA visits (years 0, 2 or 5 visits).
Results
Participant characteristics at Year 15 examination
At year 15, participants in the highest serum adiponec-
t i nq u a r t i l ew e r em o r el i k e l yt ob ew h i t e ,w o m e n ,h a v e
higher educational attainment, and be former smokers
(and less likely to be current smokers), as compared to
those in the lowest adiponectin quartile (p < 0.001;
Table 1). Consistent with previous reports, BMI, insulin
resistance (HOMA) and systemic inflammation (serum
CRP levels) were lower in the highest vs.l o w e s ta d i p o -
nectin quartile (p < 0.001; Table 1) [2,3,8]. Body mass
index, HOMA and CRP were also significantly corre-
lated with each other (rBMI, CRP = 0.53, rBMI, HOMA =
0.60 and rHOMA, CRP = 0.41, all p < 0.0001).
Year 15 serum adiponectin concentrations were positively
associated with Year 10 FVC and FEV1
Year 10 FVC was 81 ml lower in the lowest vs.h i g h e s t
adiponectin quartile (p for trend = 0.005; Table 2,
model 1). Similarly, year 10 FEV1 was 50 ml lower in
the lowest vs. highest adiponectin quartile (p for trend =
0.01; Table 2, model 1). Adjustment for either year 15
waist circumference or year 10 BMI instead of year 15
BMI in this model showed results very similar to that
observed after adjustment for year 15 BMI (data not
shown). However, after additional adjustment for insulin
resistance and systemic inflammation, year 10 FVC and
FEV1 were not associated with adiponectin (Table 2,
model 2), suggesting that these are possible mechanisms
for the adiponectin-lung function association. Year 10
FEV1/FVC was not associated with adiponectin in any
of the models (Table 2).
Year 15 serum adiponectin concentrations were positively
associated with Year 20 FVC and FEV1
Year 20 FVC was 82 ml lower in the lowest vs.h i g h e s t
adiponectin quartile (p for trend = 0.01; Table 3, model
1). Similarly, year 20 FEV1 was 38 ml lower in the low-
e s tv s .h i g h e s ta d i p o n e c t i nquartile, this difference
showed a trend towards statistical significance (p for
trend = 0.09; Table 3, model 1). Adjustment for either
year 15 waist circumference or year 20 BMI instead of
year 15 BMI in this model showed results very similar
to that observed after adjustment for year 15 BMI (data
not shown). However, after additional adjustment for
insulin resistance and systemic inflammation, year 20
FVC and FEV1 were not associated with adiponectin
(Table 3, model 2). Year 20 FEV1/FVC was not asso-
ciated with adiponectin concentrations (Table 3).
Year 15 serum adiponectin concentrations were not
associated with a ten-year decline in lung function
Ten-year decline in lung function (FVC, FEV1 or FEV1/
FVC) was not associated with year 15 serum adiponectin
Table 1 Clinical characteristics according to quartiles of year 15 serum adiponectin concentrations; CARDIA “calendar
years”.
Year 15 adiponectin quartiles (Q) Q1 (n = 565) Q2 (n = 449) Q3 (n = 519) Q4 (n = 523) p value
Age (years) 40.2 (3.7) 40.2 (3.6) 40.2 (3.6) 40.5 (3.5) 0.51
Race (% blacks) 62 46 36 27 <0.001
Sex (% men) 70 53 41 22 <0.001
Education level (completed high school or lower) (%) 26 20 17 17 <0.001
Smoking Status 0.003
Never smoker, % 65 65 65 64
Former smoker, % 14 14 19 21
Current smoker, % 21 20 16 15
Body Mass Index (kg/m2) 31.0 (6.1) 29.5 (6.9) 27.9 (6.2) 25.3 (5.2) <0.001
Physical Activity score (exercise units) 355 (301) 347 (288) 352 (286) 369 (275) 0.66
Serum C-reactive protein (g/ml) 3.9 (5.1) 3.0 (3.8) 2.8 (6.0) 1.9 (3.2) <0.001
ln (Homeostasis Model Assessment, HOMA units) 1.5 (0.5) 1.3 (0.4) 1.2 (0.4) 1.1 (0.4) <0.001
FVC at year 10 (ml) 4464 (1027) 4395 (1064) 4381 (1046) 4204 (942) <0.001
FEV1 at year 10 (ml) 3568 (775) 3507 (813) 3510 (793) 3371 (696) <0.001
FEV1/FVC at year 10 (%) 80.4 (5.5) 80.3 (5.7) 80.5 (5.5) 80.7 (6.1) 0.65
Note 1: All variables were measured at year 15 except Forced vital capacity (FVC), Forced Expiratory Volume in 1 second (FEV1) and FEV1/FVC that were measured
at year 10 and are expressed as mean (standard deviation) or percent.
Note 2: Quartile cutpoints for serum adiponectin concentrations are ≤6.99, 7.00-9.59, 9.60-14.39, and ≥ 14.40 mg/l.
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function between years 10 to 20 were strikingly similar
across all adiponectin quartiles (Table 4).
Year 15 serum adiponectin concentrations were positively
associated with peak lung function in early adulthood
Peak FVC in early adulthood (i.e. the highest value
among the years 0, 2 or 5 examinations) was 72 ml
lower in the lowest vs. highest adiponectin quartile
(4459 ml vs. 4531 ml; p for trend = 0.01). Similarly,
peak FEV1 was 46 ml lower in the lowest vs. highest
adiponectin quartile, although this difference did not
reach statistical significance (p for trend = 0.07). After
additional adjustment for insulin resistance and systemic
inflammation at year 15, peak FVC and FEV1 were not
associated with adiponectin (p for trend = 0.10 and 0.41
respectively). Peak FEV1/FVC was not associated with
adiponectin concentrations. Decline in FVC or FEV1
from peak to 20 years was also not associated with adi-
ponectin. Including lung function at year 10 in estimat-
ing peak lung function did not change the observed
associations between peak lung function and adiponec-
tin (data not shown).
In addition, there was no statistically significant inter-
action between serum adiponectin and sex in determin-
ing FVC, FEV1 or FEV1/FVC values at either years 10 or
20 examinations (p > 0.10). Analyses with logarithmi-
cally transformed adiponectin as a continuous variable
showed results very similar to those observed with adi-
ponectin analyzed as quartiles (tables 2, 3 and 4).
Discussion
This study showed that serum adiponectin concentra-
tions at the year 15 examination in the CARDIA study
Table 2 Association between year 15 serum adiponectin concentrations and year 10 lung function; CARDIA “calendar
years”.
Year 15 adiponectin quartiles (Q) YEAR 10 LUNG FUNCTION PARAMETERS (95% CI)
MODEL 1 (n = 2,056) MODEL 2 (n = 2,056)
Year 10 FVC (ml) ± SE
Q1 4298 ± 23 4327 ± 24
Q2 4353 ± 24 4357 ± 24
Q3 4420 ± 22 4409 ± 22
Q4 4380 ± 25 4357 ± 25
Q1 minus Q4 -81 (-153, -9) -30 (-103, 43)
Slope of ln(adiponectin)* -82 (-140, -23) -35 (-94, 25)
p for trend = 0.005 p for trend = 0.25
Year 10 FEV1 (ml) ± SE
Q1 3448 ± 19 3469 ± 20
Q2 3476 ± 20 3479 ± 20
Q3 3539 ± 18 3531 ± 18
Q4 3498 ± 20 3481 ± 20
Q1 minus Q4 -50 (-109, 9) -12 (-72, 48)
Slope of ln(adiponectin)* -61 (-109, -13) -27 (-76, 23)
p for trend = 0.01 p for trend = 0.28
Year 10 FEV1/FVC (%) ± SE
Q1 80.7 ± 0.2 80.6 ± 0.3
Q2 80.3 ± 0.3 80.3 ± 0.3
Q3 80.5 ± 0.2 80.5 ± 0.2
Q4 80.3 ± 0.3 80.4 ± 0.3
Q1 minus Q4 0.4 (-0.4, 1.1) 0.3 (-0.5, 1.1)
Slope of ln(adiponectin)* 0.11 (-0.51, 0.73) 0.03 (-0.61, 0.68)
p for trend = 0.73 p for trend = 0.92
Note 1: Model 1 was adjusted for race, sex, center, age, age
2, amount of self-reported physical activity, body mass index (BMI) and smoking status (never, former,
current) all at year 15 and height, height
2at year 0. Model 2 was adjusted for all covariates in model 1 and for ln(insulin resistance in HOMA units) and ln(CRP) at
year 15 examination.
Note 2: Quartile cutpoints for serum adiponectin concentrations are ≤6.99, 7.00-9.59, 9.60-14.39, and ≥ 14.40 mg/l. Mean ± standard deviation of ln(adiponectin)
= 2.21 ± 0.62 mg/l
* Unit of slope was selected to match the adiponectin difference across Q1 to Q4. It was ml/(median level of adiponectin in quartile 1 (4.8 mg/l) - median level
of adiponectin in quartile 4 (18.0 mg/l)).
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both at years 10 and 20 and these associations were
independent of BMI. Serum adiponectin concentrations
were however not associated with lung function decline
between years 10-20. The associations between adipo-
nectin and FVC and FEV1 at years 10 and 20 were no
longer significant when additionally adjusted for insulin
resistance and systemic inflammation.
Adiponectin is an anti-inflammatory adipokine. It inhi-
bits pro-inflammatory cytokines such as tumor necrosis
factor-alpha (TNF-a) and interleukin (IL)-6 and induces
anti-inflammatory cytokin e ss u c ha sI L - 1 0a n dI L - 1
receptor antagonist [20,21]. Adiponectin’s insulin-
sensitizing effect stimulates glucose utilization and fatty-
acid oxidation [22,23]. A murine model has recently
shown that genetically-induced adiponectin deficiency in
the lungs of normal-weight mice maintained on a normal
diet resulted in increased expression of TNF-a and
matrix metalloproteinases (MMP-2 and MMP-12) in
alveolar macrophages and “alveolar simplification and/or
enlargement” due to abnormal postnatal alveolar devel-
opment [15]. This murine study suggests that systemic
adiponectin, independent of obesity, may have a protec-
tive effect on the lung through inhibition of alveolar
macrophage-related inflammation.
This is the first population-based study to demonstrate
that serum adiponectin is positively associated with lung
function in humans. The difference in lung function
across adiponectin quartiles was significant after adjust-
ing for BMI or waist circumference, suggesting that it is
not simply a function of global or abdominal adiposity.
Based on current knowledge, it is likely that insulin resis-
tance and systemic inflammation are mediators of the
adiponectin-lung function association. However, the
Table 3 Association between year 15 serum adiponectin concentrations and year 20 lung function; CARDIA “calendar
years”.
Year 15 adiponectin quartiles (Q) YEAR 20 LUNG FUNCTION PARAMETERS (95% CI)
MODEL 1 (n = 2,056) MODEL 2 (n = 2,056)
Year 20 FVC (ml) ± SE
Q1 3916 ± 24 3953 ± 24
Q2 3968 ± 25 3973 ± 25
Q3 4032 ± 23 4017 ± 23
Q4 3997 ± 26 3967 ± 25
Q1 minus Q4 -82 (-156, -7) -15 (-90, 61)
Slope of ln(adiponectin)* -75 (-135, -14) -13 (-75, 49)
p for trend = 0.01 p for trend = 0.67
Year 20 FEV1 (ml) ± SE
Q1 3101 ± 20 3126 ± 20
Q2 3124 ± 21 3128 ± 20
Q3 3171 ± 19 3162 ± 19
Q4 3138 ± 21 3117 ± 21
Q1 minus Q4 -38 (-99, 24) 9 (-53, 72)
Slope of ln(adiponectin)* -42 (-92, 8) 1 (-50, 52)
p for trend = 0.09 p for trend = 0.97
Year 20 FEV1/FVC (%) ± SE
Q1 79.6 ± 0.3 79.5 ± 0.3
Q2 79.2 ± 0.3 79.2 ± 0.3
Q3 79.1 ± 0.2 79.1 ± 0.2
Q4 78.9 ± 0.3 79.0 ± 0.3
Q1 minus Q4 0.7 (-0.1, 1.5) 0.5 (-0.3, 1.4)
Slope of ln(adiponectin)* 0.45 (-0.19, 1.09) -0.30 (-0.37, 0.96)
p for trend = 0.16 p for trend = 0.37
Note 1: Model 1 was adjusted for race, sex, center, age, age
2, amount of self-reported physical activity, body mass index (BMI) and smoking status (never, former,
current) all at year 15 and height, height
2at year 0. Model 2 was adjusted for all covariates in model 1 and for ln(insulin resistance in HOMA units) and ln(CRP) at
year 15 examination.
Note 2: Quartile cutpoints for serum adiponectin concentrations are ≤6.99, 7.00-9.59, 9.60-14.39, and ≥ 14.40 mg/l. Mean ± standard deviation of ln(adiponectin)
= 2.21 ± 0.62 mg/l
* Unit of slope was selected to match the adiponectin difference across Q1 to Q4. It was ml/(median level of adiponectin in quartile 1 (4.8 mg/l) - median level
of adiponectin in quartile 4 (18.0 mg/l)).
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this study makes it difficult to definitively classify these
v a r i a b l e sa sc o n f o u n d e r so rm e d i a t o r sw h e ne v a l u a t i n g
the association between adiponectin and lung function.
Hence, we present different scenarios with and without
adjustment for these factors. Since serum adiponectin
was associated with year 10 lung function but not subse-
quent decline in lung function, it is possible that the phy-
siologic effect of serum adiponectin on lung function was
established even before year 10 of the study and that clas-
sification by year 15 serum adiponectin concentrations
might reflect lung growth abnormalities in early adult-
hood. The significant association observed between peak
FVC in early adulthood and serum adiponectin concen-
trations at year 15 further supports this suggestion. Since
serum adiponectin measurements were available about
10 years after measurement of peak lung function this
finding needs to be confirmed in other longitudinal stu-
dies. The absence of adiponectin-lung function associa-
tion after adjustment for HOMA and CRP suggests
that the adiponectin effect on lung function might be
explained by its anti-inflammatory and insulin sensitiza-
tion effects.
Our results do not agree with two small previous
cross-sectional studies of 31 and 15 patients with stable
and established COPD that showed, without adjustment
for obesity, no correlation between serum adiponectin
concentrations and spirometric lung function [24,25].
The cross sectional design, presence of COPD, older age
of subjects, confounding by BMI and limited power due
to a small sample size are possible reasons for the
observed discrepancy between these studies.
Usually, reduction in lung function with maintenance
of FEV1/FVC ratio indicates restrictive ventilatory
Table 4 Association between year 15 serum adiponectin concentrations and change in lung function over 10 years
(year 20-year 10); CARDIA “calendar years”.
Year 15 adiponectin quartiles (Q) 10 YEAR DECLINE IN LUNG FUNCTION PARAMETERS (95% CI)
MODEL 1 (n = 2,056) MODEL 2 (n = 2,056)
FVC (ml) ± SE
Q1 -383 ± 14 -374 ± 14
Q2 -385 ± 14 -383 ± 14
Q3 -389 ± 13 -392 ± 13
Q4 -383 ± 14 -390 ± 14
Q1 minusQ4 0 (-42, 42) 16 (-27, 59)
Slope of ln(adiponectin)* 7 (-27, 41) 22 (-14, 57)
p for trend = 0.69 p for trend = 0.22
FEV1 (ml) ± SE
Q1 -348 ± 11 -343 ± 11
Q2 -352 ± 12 -351 ± 12
Q3 -367 ± 11 -369 ± 11
Q4 -360 ± 12 -364 ± 12
Q1 minus Q4 12 (-22, 46) 21 (-14, 56)
Slope of ln(adiponectin)* 19 (-9, 47) 28 (-1, 56)
p for trend = 0.17 p for trend = 0.05
FEV1/FVC (%) ± SE
Q1 -1.08 ± 0.17 -1.13 ± 0.18
Q2 -1.13 ± 0.18 -1.13 ± 0.18
Q3 -1.43 ± 0.17 -1.40 ± 0.17
Q4 -1.44 ± 0.18 -1.40 ± 0.18
Q1 minus Q4 0.36 (-0.17, 0.89) 0.27 (-0.27, 0.82)
Slope of ln(adiponectin)* 0.34 (-0.09, 0.77) 0.26 (-0.18, 0.71)
p for trend = 0.11 p for trend = 0.24
Note 1: Model 1 was adjusted for race, sex, center, age, age
2, amount of self-reported physical activity, body mass index (BMI) and smoking status (never, former,
current) all at year 15 and height, height
2at year 0. Model 2 was adjusted for all covariates in model 1 and for ln(insulin resistance in HOMA units) and ln(CRP) at
year 15 examination.
Note 2: Quartile cutpoints for serum adiponectin concentrations are ≤6.99, 7.00-9.59, 9.60-14.39, and ≥ 14.40 mg/l. Mean ± standard deviation of ln(adiponectin)
= 2.21 ± 0.62 mg/l
* Unit of slope was selected to match the adiponectin difference across Q1 to Q4. It was ml/(median level of adiponectin in quartile 1 (4.8 mg/l) - median level
of adiponectin in quartile 4 (18.0 mg/l)).
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chest wall or reduced neuromuscular strength. Similar
to observations made in mice models, inadequate alveo-
lar morphogenesis may present with restrictive ventila-
tory abnormalities in humans. Another potential
explanation includes the effect of adiponectin on periph-
eral or smaller airways (and associated premature airway
closure and hyperinflation resulting in pseudo-restric-
tion [26]). Similar small airway physiologic abnormal-
ities, with thickened alveolar walls, have been previously
d e s c r i b e di np a t i e n t sw i t hd i a b e t e sm e l l i t u s[ 2 7 , 2 8 ] .
A recent study showed that phosphate buffered saline
inhalation by adiponectin-deficient mice produced
greater decrease in lung compliance compared to wild-
type mice. The investigators suggested that this may be
due to an increase in small airway closure from reduced
lung elastic recoil [29]. Future studies with static lung
volume estimation may help clarify the precise physiolo-
gical changes associated with reduced serum adiponectin
concentrations in humans.
The immediate clinical relevance of our finding of a
modest association between serum adiponectin and lung
function in young adults is unclear. It is nonetheless sig-
nificant in the context of an epidemiological study
because even modestly lower lung function early in life
is associated with increased risk for both future lung
[30] and cardiovascular diseases [31-33]. Since an
inflammatory pulmonary milieu may increase the risk
for adverse reactions to other occupational and environ-
mental exposures manipulation of systemic adiponectin
concentrations in early life (such as with diet, exercise,
weight loss and medications) may have long-term effects
on lung development, injury and remodeling.
The present study has several strengths, including the
large number of generally healthy participants, inclusion
of blacks and women, high quality spirometry data col-
lected over a ten-year period, confirmation in a human
population of findings demonstrated more mechanisti-
cally in a mouse-model, and excellent retention of the
original cohort.
One limitation of the study is that the measurements
of lung function (years 10 and 20) and serum adiponec-
tin (year 15) did not coincide. As a result, it is not possi-
ble to establish temporality of associations definitively.
Another limitation is the inability of the adiponectin
assay to distinguish between its different multimeric
forms. Thus, this study could not evaluate potential bio-
logical differences in multimeric forms of adiponectin
on lung function. We have limited information on lung
function values at very high adiponectin concentrations
(adiponectin concentrations ≥30 mg/L, which was the
99
th percentile in our data). We reduced the influence
of these high values by studying natural logarithmically
transformed adiponectin and discuss this methodological
issue further in the online supplement (Additional
File 1). Finally, serum adiponectin concentrations may
not reflect airway adiponectin concentrations.
In summary, this translational epidemiological study
supports the hypothesis that lower serum adiponectin
concentrations are associated with lower lung function
in young adults. It further suggests that this association
is independent of obesity and possibly mediated by insu-
lin resistance and systemic inflammation. Longitudinal
studies with long-term follow-up using non-invasive
tests of peripheral airway function will help us evaluate
the association between serum adiponectin concentra-
tions in early adulthood and risk of lung and cardiovas-
cular disease in later life.
Additional material
Additional file 1: Influence of the rare high adiponectin values:
representing the predictor (adiponectin) as untransformed vs. log
transform of adiponectin. This file provides a detailed description of
the distribution of adiponectin concentrations in the CARDIA study and
describes the rationale for analyzing adiponectin as a log transformed
variable (when analyzed as a continuous variable).
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